After Vivus (NASDAQ:VVUS) posted earnings last week, the company's share price took a big hit due to unimpressive sales of obesity drug Qsymia. With competitor Arena Pharmaceuticals (NASDAQ:ARNA) and its partner Eisai poised to enter this space with its own drug Belviq in the first quarter of next year, VIVUS might be starting to feel pressure to boost sales.
While investors need to continue watching Qsymia sales quarter to quarter, VIVUS looks determined to expand the possible uses for its flagship drug. In this video, Health Care Analyst Max Macaluso discusses a new clinical study that suggests Qsymia might widen its indication in the future.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.